Swedish Orphan Biovitrum (OTCMKTS:BIOVF) AB (OTCMKTS:BIOVF), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company dedicated to developing and delivering treatments for rare diseases. Established in 2001, Sobi has built a reputation for focusing on conditions with high unmet medical need, particularly within hematology, immunology and genetic metabolic disorders. Through in‐house research and strategic partnerships, the company aims to bring innovative therapies to patients who often have limited treatment options.
Sobi’s portfolio includes products for hereditary angioedema, hemophilia A and B, and rare metabolic conditions. Key marketed therapies include a long‐acting factor VIII product for hemophilia A, a factor IX product for hemophilia B, and enzyme replacement treatments for inherited metabolic disorders. The company also holds rights to immunology treatments such as interleukin inhibitors and supports ongoing clinical development programs targeting both pediatric and adult patient populations.
The company operates across Europe, North America, Latin America, the Middle East and Asia Pacific, with regional offices and distribution networks in more than 25 countries. Sobi collaborates with global research institutions, biotechnology partners and patient advocacy groups to advance its pipeline and ensure access to therapies worldwide. This geographic footprint enables the company to address diverse regulatory environments and tailor patient support services to local needs.
Under the leadership of Chief Executive Officer Richard Francis, Sobi continues to invest in both internal research and transactions that expand its rare disease expertise. The company’s governance structure includes an experienced board of directors with backgrounds in pharmaceuticals, finance and global health. Sobi’s strategic priorities emphasize sustainable growth, scientific innovation and strengthening patient support programs for the rare disease community.
